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Abstract The major protein zero (MPZ) is involved in
peripheral myelin folding. Using nested reverse transcription-
PCR, we amplified several fragments of MPZ mRNAs in white
blood cells and in peripheral nerve tissue. Cloning of PCR
products revealed the existence of three alternative splicing
patterns: one resulted in the complete loss of exon 3 and two
others induced partial skipping of the exon 3 sequence. All three
alternative splicing mechanisms produced a frame-shift and
created an identical premature stop codon in exon 4. We
conclude that the existence of these MPZ RNA transcript
variants may be the result of deliberate splicing decisions and
may have functional implications in the cell.
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1. Introduction
Peripheral myelin is a highly ordered and compact exten-
sion of the Schwann cell membrane [1]. The major protein
zero (MPZ) is an abundant transmembrane adhesion molecule
[2]. Homophilic interaction between its extracellular part leads
to a tight wrapping of myelin around the axon [3,4]. The
MPZ gene is located on chromosome 1q21.3-23 and has a
size of 6 kb [5]. This gene contains six exons [6] and encodes
a 1948 nucleotides long mRNA [5]. At least 56 mutations in
the MPZ gene have been described as implicated in a periph-
eral neuropathy called Charcot-Marie-Tooth disease type 1B
[7]. The majority of mutations are more particularly located in
exons 2 and 3 of the MPZ gene and a¡ect the extracellular
domain of the protein. One silent polymorphism has been
reported in exon 3 in a French family a¡ected by CMT1
[8]. Such an observation may suggest that this silent polymor-
phism may promote MPZ missplicing and could be involved
in the etiology of the disease. To the best of our knowledge,
no information is available concerning the composition of
human MPZ mRNA transcripts and no secondary transcrip-
tion products have previously been reported in rat [3]. Since
the silent polymorphism occurs in exon 3, we decided to in-
vestigate the splicing of this exon.
2. Materials and methods
2.1. Patient selection
Four subjects from the Ho“pital Neurologique of Lyon (52 þ 12 year
old men) were studied. They su¡ered from non-hereditary neuropa-
thies and were not classi¢ed as CMT patients. Single strand confor-
mation polymorphism analysis of MPZ exons revealed no alteration
in the MPZ gene (data not shown). This result permitted us to select
them as control subjects for studying splicing of the MPZ mRNA in
exon 3.
2.2. Sample preparation
Peripheral blood and fragments of peripheral nerve tissue (sural
nerve biopsies) were collected from each subject after informed con-
sent. Genomic DNA was puri¢ed from 10 ml of frozen blood using a
QIAamp blood kit (Qiagen GmbH, Hilden, Germany). PolyA+
mRNAs from white blood cells (WBCs) were extracted in duplicate
from 200 Wl of fresh blood with the PolyAtract system 1000 kit
(Promega, Madison, WI, USA) according to manufacturer’s protocol.
In the ¢nal step, mRNAs were eluted at 72‡C in 30 Wl of RNAse-free
water. Total cellular RNAs were isolated from peripheral nerve tissue
using RNAxel solution (Eurobio, Les Ulis, France). Due to poor
quantities of nerve tissue, extractions were not carried out in dupli-
cate. Absence of genomic DNA in the di¡erent RNA preparations
was checked by two successive ampli¢cations of L-actin DNA with
primers chosen in di¡erent exons of this gene.
2.3. 5P End labelling
Labelling was for 1 h at 37‡C on 20 pmol of primer, 2 WCi of
[K-32P]ATP (3000 Ci/mmol, Amersham Pharmacia Biotech Europe,
Freiburg, Germany) and 2 U of T4 polynucleotide kinase (Promega).
Labelled primer was then puri¢ed using a Microbiospin 6 chromatog-
raphy column (Bio-Rad, Hercules, CA, USA) according to the man-
ufacturer’s protocol.
2.4. Ampli¢cation and quanti¢cation of MPZ mRNAs
cDNA was synthesised by the oligo-dT primer method, with Mur-
ine Moloney Leukemia Virus Reverse Transcriptase (Eurobio), using
either 10 Wl of polyA+ mRNA or 750 ng of the total RNA prepara-
tion. cDNA was then diluted with water to a ¢nal volume of 100 Wl.
MPZ cDNA was ampli¢ed using two steps of nested PCR. In the
¢rst step, the PCR reaction (PCR1) was in a ¢nal volume of 50 Wl
using primer set 1 (Table 1). The applied reaction conditions were
30 cycles of 45 s at 95‡C, 45 s at 56‡C and 1 min at 72‡C, using
10 Wl of denatured cDNA template, 20 pmol of forward and reverse
primers, 1 U of inorganic pyrophosphatase (Eurobio) and 0.25 U of
Eurobluetaq (Eurobio). PCR was completed by a terminal elongation
of 7 min at 72‡C. The number of cycles was chosen in order to be in
the exponential phase of PCR. First step PCR products were puri¢ed
in order to remove enzymes and primers using the QIAquick PCR
puri¢cation kit (Qiagen).
In the second nested PCR (PCR2), the applied conditions were
25 cycles of 1 min at 95‡C, 1 min at 56‡C and 1 min and 30 s at
72‡C in order to be in the exponential part of the PCR ampli¢cation.
PCR2 was done on 0.3 Wl of the puri¢ed and denatured PCR1 prod-
ucts, in the presence of 20 pmol of forward primer, 18 pmol of reverse
primer and 2 pmol of labelled reverse primer (Table 1) and 0.25 U of
Eurobluetaq.
Electrophoresis of 10 Wl of PCR2 products was conducted on a
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3.5% acrylamide gel for 2 h at 120 V. The gel was then air-dried and
exposed for 5 h at 380‡C to a BioMax MS ¢lm using a BioMax MS
intensifying screen (Eastman Kodak Company, Rochester, NY, USA)
for autoradiography. Quanti¢cation was done on a Phosphoimager SI
(Molecular Dynamics, Sunnyvale, CA, USA). Air-dried gels were ex-
posed for 2 h in an exposure cassette (Molecular Dynamics). Quanti-
¢cation of radioactivity was then carried out with Image Quant v2.1
software (Molecular Dynamics).
2.5. Ampli¢cation of L-actin mRNAs
L-Actin RNA was ampli¢ed from 1 Wl of cDNA templates by PCR.
Reaction was in a ¢nal volume of 25 Wl using L-actin-speci¢c primers
(Table 1). The applied reaction conditions were 30 cycles of 1 min at
95‡C, 1 min at 62‡C, 1 min and 30 s at 72‡C using 1 Wl of denatured
cDNA templates, 20 pmol forward primer, 18 pmol reverse primer,
2 pmol labelled reverse primer and 0.25 U Eurobluetaq. These con-
ditions were chosen in order to be in the exponential part of the PCR
ampli¢cation. Electrophoresis and quanti¢cation were proceeded as
previously described.
2.6. DNA sequencing
PCR2 products were cloned in the pGEM-T easy vector (Promega)
according to the manufacturer’s protocol. Plasmids containing di¡er-
ent inserts were sequenced with the ABI Prism dRhodamine Termi-
nator Cycle Sequencing Ready Reaction kit and an ABI Prism 310
Genetic Analyser automatic sequencer (Perkin Elmer, Branchburg,
NJ, USA).
2.7. Statistical analysis
Each PCR was realised in duplicate on each RNA preparation. The
quantity of radioactivity signals for each MPZ mRNA variant was
adjusted with the L-actin signal as reference. Results were then ana-
lysed using the non-parametric Mann-Whitney test.
3. Results and discussion
Primer set 2 (PCR2, Table 1) used to amplify ¢rst step PCR
products revealed a complex PCR pattern (Fig. 1). In WBCs,
a signal with a length of 365 bp corresponding to a normally
spliced transcription product was visible (E3N RNA variant:
Fig. 1). In addition, shorter fragments were also found. In
nerve tissue, as expected, the predicted fragment for MPZ
RNA was ampli¢ed abundantly. As seen in blood, the same
shorter transcription fragments were observed (Fig. 1).
Illegitimate transcription of tissue-speci¢c genes has been
demonstrated in a large number of cell types, especially
WBCs [9^12]. In our work, we demonstrate that the periph-
eral myelin gene MPZ is expressed in WBCs. Comparison
with the L-actin signals revealed that the concentration of
the normally spliced MPZ mRNA was 25 times more abun-
dant in peripheral nerve tissue than in WBCs (P6 0.001, Ta-
ble 2).
In order to characterise the shorter transcription fragments,
PCR products from the second ampli¢cation step were cloned
in the pGEM-T easy vector. More than 100 clones were size-
selected and four of them with inserts corresponding to 365,
151, 190 and 220 bp were sequenced. In addition to the nor-
mal 365 bp splicing product of MPZ RNA (E3N), we ob-
tained three other sequences corresponding to (i) the complete
removal of exon 3 (E3‡), (ii) partial exon 3 skipping between
nucleotides 274 (nucleotide +1 is A of initiator AUG) and 448
(E3v274^448) and (iii) partial exon 3 skipping between nu-
cleotides 304 and 448 (E3v304^448) (Fig. 2). These di¡erent
splicing patterns lead to the ampli¢cation of four PCR2 frag-
ments with respective lengths of 365, 151, 190 and 220 bp.
All three small RNA variants were expressed in WBCs and
peripheral nerve tissue (Fig. 1). In WBCs, only the E3‡ variant
was slightly more expressed than the other RNAs (P6 0.01,
Table 2). In peripheral nerve tissue, the normally spliced RNA
was much more abundant than the three small RNA variants
(P6 0.001, Table 2). Comparison between the levels of ex-
pression for the three small RNA variants revealed no signi¢-
cant di¡erence between WBCs and peripheral nerve tissue.
This ¢nding allows us to suggest that (i) illegitimate tran-
scripts of MPZ detected in blood are also present in periph-
eral nerve tissue of control subjects. This result is consistent
with aberrant splicing also found for genes encoding argini-
nosuccinate lyase and adenosine deaminase, among others
[11]. For the dystrophin gene, only one case of an alternative
splicing product has been found in WBCs but not in muscle
[13]. Thus, we may conclude that, with di¡erences in quantity,
the illegitimate transcription of the MPZ gene in WBCs re-
£ects tissue-speci¢c transcription of MPZ. (ii) The MPZ gene
is submitted to di¡erent alternative splicing patterns. It has
previously been described that only one isoform of MPZ
RNA is observed in rat peripheral nerve [3], but this result
is probably due to the limited resolution of the applied North-
ern blotting technique. In humans, MPZ transcription may
di¡er by expression of three additional small RNA variants,
which are not di¡erently and signi¢cantly expressed between
WBCs and peripheral nerve tissue.
Table 1
Primer sequences
Forward primers Reverse primers
PCR1 TGAGTGGGTCTCAGATGACA (bases 165^184 in exon 2) TCTTATCCTTGCGAGACTCC (bases 742^723 in exon 6)
PCR2 GTCTCAGATGACATCTC (bases 172^188 in exon 2) ACCACGTAGAAAAGCAGCAG (bases 536 to 517 in exon 4)
PCR L-actin GCACTCTTCCAGCCTTCC (bases 779^795 in exon 4) GCGCTCAGGAGGAGCAAT (bases 1005^988 in exon 6)
Bases correspond to RNA sequences, +1 is the A of the initiation codon. MPZ GenBank accession number: D14583, L-actin GenBank acces-
sion number: X00351.
Fig. 1. Exon 3 splicing pattern of MPZ RNAs. Reverse-transcribed
RNAs of WBCs and peripheral nerve tissue (N) were ampli¢ed (a)
by nested PCR with MPZ-speci¢c primers chosen to amplify exon
3, (b) by a single PCR with L-actin-speci¢c primers. 32P-labelled re-
verse primer was used either in the second round of PCR for MPZ
or in the single PCR for L-actin. PCR products were electropho-
resed in 3.5% acrylamide and exposed for autoradiography.
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Each of the two new alternative splicing sites described here
occurred at a consensus acceptor intron site: GU. Sequence
analysis of the three small RNA variants for MPZ revealed a
reading frame-shift, which leads in each case to the same
premature termination codon (PTC) at position 482^484 of
exon 4. Transcripts containing a PTC in their sequence have
been described in the hMSH2 gene by Marshall et al. [14].
They showed the existence of two additional transcripts for
the hMSH2 gene where alternative splicing mechanisms pro-
duced the appearance of two di¡erent PTCs. They pointed
out that the presence of sequences which show similarity to
previously described mRNA destabilising motifs downstream
of each of the two PTCs might bring transcription variants to
a rapid degradation [14]. Moreover, many reports have shown
that mutations in several genes like the dystrophin gene [10],
the Fanconi anaemia group C gene [15], the CFTR gene [16],
the ¢brillin gene [17] and the neuro¢bromatosis type 1 gene
[18] may produce PTCs, but also that alternative splicing of
PTC containing exons may occur. These splicing alterations
result in mRNAs that either lack the PTC or disrupt the
frame-shift generated by the PTC so as to encode an almost
normal but shortened protein. Concerning the MPZ gene,
normal alternative splicings described in control subjects
lead to PTCs containing small RNA variants. However,
none of the described destabilising motifs [19^22] is found
downstream of the PTC. Thus, the existence of these PTC
containing RNAs for the MPZ gene may re£ect deliberate
splicing mechanisms, suggesting a functional role of these
transcripts in the cell.
Moreover, a silent polymorphism (GTGCGTA) at posi-
tion +276 in CMT1 patients has been described in a French
family (family CMT-R, in [8]). This silent polymorphism was
present in three patients as well as in two asymptomatic sub-
jects. Using the HSPL version 2 (prediction of splice sites in
human DNA sequences) program available at http://
gc.bcm.tmc.edu:8088/search-launcher.html [23,24], it was pos-
sible to calculate splicing scores (0.76 is the threshold of the
program), which give a value for the likelihood to use a nu-
cleotide as a site for splicing [23,24] for the MPZ gene. The
HSPL program does not predict the splicing site at position
+274, although we found this site to be used in one of the
alternative transcripts. But, the program indicates the creation
of this splicing site when the GTGCGTA polymorphism oc-
curs (splicing score 0.80). Thus, we hypothesise that this poly-
morphism may enhance the e⁄ciency of the splicing site at
position +274. Unfortunately, no nerve tissue from these
CMT1 patients was available and we were unable to con¢rm
this hypothesis.
Also, a recent report has shown the existence of high titres
IgG auto-antibodies in sera of patients with in£ammatory
neuropathies which are able to recognise, in the peripheral
but not the central nervous system, a protein of 36 kDa re-
lated to MPZ [25]. As MPZ proteins associate to form tet-
ramers, the encoded proteins by the MPZ small RNA var-
iants might assemble and form this 36 kDa MPZ-related
protein.
To our knowledge, this is the ¢rst description of a poly-
morphism that may alter the transcription of a small RNA
variant of a gene. It remains necessary to further investigate
the translation of the small RNA variants of the MPZ gene
and their possible function.
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